Christiane Otto

Summary

Affiliation: Bayer HealthCare AG
Country: Germany

Publications

  1. ncbi In vivo characterization of estrogen receptor modulators with reduced genomic versus nongenomic activity in vitro
    Christiane Otto
    Research Laboratories, Bayer Schering Pharma AG, D 13353 Berlin, Germany
    J Steroid Biochem Mol Biol 111:95-100. 2008
  2. ncbi Comparative analysis of the uterine and mammary gland effects of progesterone and medroxyprogesterone acetate
    Christiane Otto
    TRG Women s Healthcare, Bayer Schering Pharma AG, Muellerstrasse 178, 13342 Berlin, Germany
    Maturitas 65:386-91. 2010
  3. ncbi GPR30 does not mediate estrogenic responses in reproductive organs in mice
    Christiane Otto
    Therapeutic Research Group Women s Healthcare, Bayer Schering Pharma AG, 13353 Berlin, Germany
    Biol Reprod 80:34-41. 2009
  4. ncbi Comparative analysis of the uterine and mammary gland effects of drospirenone and medroxyprogesterone acetate
    Christiane Otto
    TRG Women s Healthcare, Bayer Schering Pharma AG, Mullerstrasse 178, 13353 Berlin, Germany
    Endocrinology 149:3952-9. 2008
  5. ncbi G protein-coupled receptor 30 localizes to the endoplasmic reticulum and is not activated by estradiol
    Christiane Otto
    Therapeutic Research Group Women s Healthcare, Bayer Schering Pharma AG, Mullerstrasse 178, 13342 Berlin, Germany
    Endocrinology 149:4846-56. 2008
  6. ncbi DNA binding by estrogen receptor-alpha is essential for the transcriptional response to estrogen in the liver and the uterus
    Dörthe L Ahlbory-Dieker
    Bayer Schering Pharma AG, Therapeutic Research Group Women s Healthcare, Mullerstrasse 178, 13353 Berlin, Germany
    Mol Endocrinol 23:1544-55. 2009
  7. ncbi In vitro characterization of ZK 230211--A type III progesterone receptor antagonist with enhanced antiproliferative properties
    Wiebke Afhüppe
    Bayer Schering Pharma AG, TRG Women s Healthcare, Müllerstr 178, D 13342 Berlin, Germany
    J Steroid Biochem Mol Biol 119:45-55. 2010
  8. ncbi A critical review of fundamental controversies in the field of GPR30 research
    Gernot Langer
    Lead Generation and Optimization, Screening Berlin, Bayer Schering Pharma AG, 13342 Berlin, Germany
    Steroids 75:603-10. 2010
  9. ncbi Impaired left-ventricular cardiac function in male GPR30-deficient mice
    Martina Delbeck
    Cardiology Research, Bayer Schering Pharma AG, 42096 Wuppertal, Germany
    Mol Med Rep 4:37-40. 2011
  10. ncbi A dual estrogen receptor TR-FRET assay for simultaneous measurement of steroid site binding and coactivator recruitment
    Tarek Hilal
    Lead Generation and Optimization, Screening, Bayer Schering Pharma AG, Muellerstr 178, 13342 Berlin, Germany
    J Biomol Screen 15:268-78. 2010

Collaborators

  • Jens Hoffmann
  • Stefan Schafer
  • Anette Sommer
  • Mathias Zink
  • Vladimir Todorov
  • Ulla G Friis
  • R Maldonado
  • Johanna M Beekman
  • Gunther Schutz
  • Martina Delbeck
  • Jörg Isensee
  • Benjamin Bader
  • Tarek Hilal
  • Gernot Langer
  • Wiebke Afhüppe
  • Dörthe L Ahlbory-Dieker
  • Rosanna Parlato
  • Matthias Hautmann
  • Silja Wessler
  • Miquel Martin
  • Tim Hucho
  • Stefan Golz
  • Wiebke Janssen
  • Richardus Vonk
  • Patricia Ruiz Noppinger
  • Daniel Korr
  • Vera Puetter
  • Karsten Parczyk
  • Ulrike Fuhrmann
  • Luca Meoli
  • Carsten Möller
  • Jenny Schkoldow
  • Gabriele Leder
  • Tim M Wintermantel
  • Susanne Trölenberg
  • Brenda D Stride
  • Henrik Seidel
  • Malcolm G Parker
  • Florian Segerer
  • Hayo Castrop
  • Stephanie Stotz
  • Yvonne Begus
  • Michael Desch
  • Frank Schweda
  • Nicola Wilck
  • Karl-Heinrich Fritzemeier
  • Karl Heinrich Fritzemeier
  • Verena Stangl
  • Joseba Pineda
  • Maria Torrecilla
  • Maria Teresa Santamarta

Detail Information

Publications16

  1. ncbi In vivo characterization of estrogen receptor modulators with reduced genomic versus nongenomic activity in vitro
    Christiane Otto
    Research Laboratories, Bayer Schering Pharma AG, D 13353 Berlin, Germany
    J Steroid Biochem Mol Biol 111:95-100. 2008
    ..We conclude that pathway-selective ER ligands may represent an interesting option for hormone therapy...
  2. ncbi Comparative analysis of the uterine and mammary gland effects of progesterone and medroxyprogesterone acetate
    Christiane Otto
    TRG Women s Healthcare, Bayer Schering Pharma AG, Muellerstrasse 178, 13342 Berlin, Germany
    Maturitas 65:386-91. 2010
    ..In a quantitative mouse model, we assessed the balance between uterine and undesired mammary gland effects for two progestins that are widely used in HRT, progesterone and medroxyprogesterone acetate...
  3. ncbi GPR30 does not mediate estrogenic responses in reproductive organs in mice
    Christiane Otto
    Therapeutic Research Group Women s Healthcare, Bayer Schering Pharma AG, 13353 Berlin, Germany
    Biol Reprod 80:34-41. 2009
    ..We conclude that the perception of Gpr30 (based on homology related to peptide receptors) as an ER might be premature and has to be reconsidered...
  4. ncbi Comparative analysis of the uterine and mammary gland effects of drospirenone and medroxyprogesterone acetate
    Christiane Otto
    TRG Women s Healthcare, Bayer Schering Pharma AG, Mullerstrasse 178, 13353 Berlin, Germany
    Endocrinology 149:3952-9. 2008
    ..We hypothesize that the safety of combined hormone therapy in postmenopausal women may be associated with a dissociation between the uterine and mammary gland activities of the progestin component...
  5. ncbi G protein-coupled receptor 30 localizes to the endoplasmic reticulum and is not activated by estradiol
    Christiane Otto
    Therapeutic Research Group Women s Healthcare, Bayer Schering Pharma AG, Mullerstrasse 178, 13342 Berlin, Germany
    Endocrinology 149:4846-56. 2008
    ..In two classical estrogen target organs, the uterus and the mammary gland, G1 did not show any estrogenic effect. Taken together, we draw the conclusion that GPR30 is still an orphan receptor...
  6. ncbi DNA binding by estrogen receptor-alpha is essential for the transcriptional response to estrogen in the liver and the uterus
    Dörthe L Ahlbory-Dieker
    Bayer Schering Pharma AG, Therapeutic Research Group Women s Healthcare, Mullerstrasse 178, 13353 Berlin, Germany
    Mol Endocrinol 23:1544-55. 2009
    ..The analyses indicate that both gene activation and repression by estrogen-bound ERalpha rely on an intact DBD in vivo...
  7. ncbi In vitro characterization of ZK 230211--A type III progesterone receptor antagonist with enhanced antiproliferative properties
    Wiebke Afhüppe
    Bayer Schering Pharma AG, TRG Women s Healthcare, Müllerstr 178, D 13342 Berlin, Germany
    J Steroid Biochem Mol Biol 119:45-55. 2010
    ..In summary, our studies demonstrate ZK 230211 to be a type III progesterone receptor antagonist which is characterized by very strong DNA binding activity and strong antiproliferative effects in the cancer cell lines HeLa and T47D...
  8. ncbi A critical review of fundamental controversies in the field of GPR30 research
    Gernot Langer
    Lead Generation and Optimization, Screening Berlin, Bayer Schering Pharma AG, 13342 Berlin, Germany
    Steroids 75:603-10. 2010
    ..In the second part, we discuss the strengths and limitations of four available GPR30 mouse models. We elucidate the potential impact of different targeting strategies on phenotypic diversity...
  9. ncbi Impaired left-ventricular cardiac function in male GPR30-deficient mice
    Martina Delbeck
    Cardiology Research, Bayer Schering Pharma AG, 42096 Wuppertal, Germany
    Mol Med Rep 4:37-40. 2011
    ..In conclusion, our data support a role for GPR30 in the gender-specific aspects of heart failure...
  10. ncbi A dual estrogen receptor TR-FRET assay for simultaneous measurement of steroid site binding and coactivator recruitment
    Tarek Hilal
    Lead Generation and Optimization, Screening, Bayer Schering Pharma AG, Muellerstr 178, 13342 Berlin, Germany
    J Biomol Screen 15:268-78. 2010
    ..The simple 1-step mix-and-measure protocol gives excellent quality and robustness and can be miniaturized to 5-microL volume...
  11. ncbi Identification of estrogen receptor ligands leading to activation of non-genomic signaling pathways while exhibiting only weak transcriptional activity
    Silja Wessler
    Paul Ehrlich Institute, Paul Ehrlich Strasse 51 59, D 63225 Langen, Germany
    J Steroid Biochem Mol Biol 98:25-35. 2006
    ..We assume that these pathway-selective estrogen receptor ligands may serve as potent lead structures for novel hormone replacement strategies exhibiting lesser side effects than the existing treatment paradigms...
  12. ncbi Specific ablation of the transcription factor CREB in sympathetic neurons surprisingly protects against developmentally regulated apoptosis
    Rosanna Parlato
    Department of Molecular Biology of the Cell I, German Cancer Research Center, Heidelberg, Germany
    Development 134:1663-70. 2007
    ..Thus, our analysis indicates that the activity of cell-autonomous pro-survival signalling is operative in developing sympathetic neurons in the absence of CREB...
  13. ncbi Pituitary adenylate cyclase-activating polypeptide stimulates renin secretion via activation of PAC1 receptors
    Matthias Hautmann
    Institute for Physiology, University of Regensburg, 93040 Regensburg, Germany
    J Am Soc Nephrol 18:1150-6. 2007
    ..These data show that PACAP acting on PAC1 receptors potently stimulates renin release, serving as a tonic enhancer of the renin system in vivo...
  14. ncbi Pulmonary hypertension and right heart failure in pituitary adenylate cyclase-activating polypeptide type I receptor-deficient mice
    Christiane Otto
    Division of Molecular Biology of the Cell, German Cancer Research Center, Heidelberg, Germany
    Circulation 110:3245-51. 2004
    ..To define the physiologic role of the PACAP-preferring type I receptor, PAC1, in cardiopulmonary function, we developed a mutant mouse strain lacking functional PAC1 receptors...
  15. ncbi Reduced expression of brain-derived neurotrophic factor in mice deficient for pituitary adenylate cyclase activating polypeptide type-I-receptor
    Mathias Zink
    Central Institute of Mental Health, P O Box 12 21 20, D 68072 Mannheim, Germany
    Neurosci Lett 360:106-8. 2004
    ..Our data demonstrate that even in vivo PAC1-mediated signaling seems to play a pivotal role for the transcriptional regulation of BDNF...
  16. ncbi Morphine withdrawal is modified in pituitary adenylate cyclase-activating polypeptide type I-receptor-deficient mice
    Miquel Martin
    Laboratory of Neuropharmacology, Faculty of Medicine, University Pompeu Fabra, c Doctor Aiguader 80, 08003 Barcelona, Spain
    Brain Res Mol Brain Res 110:109-18. 2003
    ..These data therefore suggested that most likely disruption of PAC1-mediated signalling in afferents towards the locus coeruleus but not within the intrinsic locus coeruleus system led to the enhancement of somatic withdrawal signs...